EGFR and non-small cell lung carcinoma: In addition, the effects of a miR-146a mimic was examined when combined with EGFR TKIs (gefitinib, erlotinib, and afatinib) and a monoclonal antibody (cetuximab) specifically in NSCLC cell lines that are resistant to EGFR TKIs.